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A B S T R A C T
Progress in genetic engineering led to the emergence of some viruses as potent anticancer therapeutics. These
oncolytic viruses combine self-amplification with dual antitumor action: oncolytic (destruction of cancer cells)
and immunostimulatory (eliciting acquired antitumor response against cancer epitopes). As any other viruses,
they trigger antiviral response upon systemic administration.
Mesenchymal stem cells are immature cells capable of self-renewing and differentiating into many cell types
that belong to three germinal layers. Due to their inherent tumor tropism mesenchymal stem cells loaded with
oncolytic virus can improve delivery of the therapeutic cargo to cancer sites. Shielding of oncolytic viral con-
struct from antiviral host immune response makes these cells prospective delivery vehicles to even hard-to-reach
metastatic neoplastic foci.
Use of mesenchymal stem cells has been criticized by some investigators as limiting proliferative abilities of
primary cells and increasing the risk of malignant transformation, as well as attenuating therapeutic responses.
However, majority of preclinical studies indicate safety and efficacy of mesenchymal stem cells used as carriers
of oncolytic viruses. In view of contradictory postulates, the debate continues.
The review discusses mesenchymal stem cells as carriers for delivery of genetically engineered oncolytic
constructs and focuses on systemic approach to oncoviral treatment of some deadly neoplasms.
1. Introduction
Despite unquestionable progress in cancer treatment, several ma-
lignancies still tend to elude successful cure or medically-induced re-
mission. Continued rise in morbidity in the last twenty years for
gliomas, melanoma or pancreatic cancer makes them a major public
health concern and a research challenge. Although radically improved
outcomes might be unattainable yet, stepwise progress is likely with
novel or improved treatments involving immunotherapy, cell-based
therapeutics, oncolytic virotherapy and hybrid approaches.
Intriguing recoveries from cancer following natural viral infection
(e.g. measles) have been known to medicine since early 20th century
but this early lead based on use of wild-type adenovirus, poliovirus or
Coxsackie virus was marred by virus-associated morbidity and com-
plications and was later abandoned (Kelly and Russell, 2007). Clinical
utility of oncolytic viruses has been steadily regaining ground since the
latter part of the 20th century with advances in genetic engineering.
Current generation of many oncolytic viral constructs allows targeting
and destroying cancer cells while toxicities to surrounding normal
tissues are minimized.
A concurrent development in cell-based anticancer therapies has led
to the concept of oncoviral viruses’ delivery to tumors via cellular
carriers. It assumes that certain types of cells pre-loaded ex vivo with
some curative cargo can be administered systemically, delivered to and
released in target tissues.
This review highlights therapeutic use of mesenchymal stem cells
(MSCs) preloaded ex vivo with oncolytic viral cargo to deliver the virus
to tumor foci following reinfusion into bloodstream (Fig. 1). This
“Trojan horse” approach fits well with carrier cells that possess natural
tropism or are targetable to disseminated/metastatic tumor beds.
2. Mesenchymal stem cells: an overview
2.1. Origin, phenotype and differentiation
Friedenstein and colleagues identified in the 1970s a subpopulation
of non-hematopoietic cells in bone marrow with morphology akin to
that of fibroblasts; these cells were able to form colonies in vitro, and
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came to be known as CFU-F (colony forming unit-fibroblastoid) cells
(Friedenstein et al., 1976). Because of their ability to renew and dif-
ferentiate, these multipotent stromal cells derived from bone marrow
were agreed upon as stem cells and dubbed mesenchymal stem cells
(MSCs). MSCs occurring in bone marrow constitute a heterogeneous
population that comprises a mixture of hematopoietic progenitors ori-
ginating from mesoderm and constituting only a small percentage of
self-renewing stem cells (Uccelli et al., 2008). In 2005 and 2006, ISCT
(International Society for Cellular Therapy) recommended replacing
the term “stem” with “stromal” and considering candidate cells as MSCs
only if they could demonstrate solely adherent replication and pre-
sented (or lacked) the following surface antigens: CD73+, CD90+,
CD105+, CD14−, CD34−, CD45− CD11b-, CD19− and CD79α-, to-
gether with the ability to differentiate into osseous, cartilage and adi-
pose cells. MSCs also express low level of major histocompatibility
complex (MHC) class I molecules and do not express MHC class II on the
cell surface, rendering allogeneic transplants feasible. Despite the ISCT
recommendation, the term “stem” still remains in general common use
to define MSCs (Dominici et al., 2006; Lv et al., 2014).
MSCs derived from various tissues share common features but they
can vary in their differentiation and angiogenic properties. Bone
marrow and adipose tissues are the main common sources of MSCs
(called BM-MSCs and ADSCs, respectively), chiefly due to the ease of
material collection, but MSCs can also be isolated from e.g. umbilical
cord blood, menstrual blood, Wharton's jelly, placenta and several other
tissues. Lv et al. have demonstrated that only a small fraction of the
cells in isolated MSC populations are genuine stem cells with potential
for bona fide three-dimensional differentiation. They also proposed
other specific markers to stress the stemness of MSCs, including Stro-1,
SSEA-4 and CD146 (Lv et al., 2014). Significant differences were
claimed between MSCs derived from newborn and adult tissues, with
the former showing less differentiation and higher survival potential
(Hass et al., 2011). A specific marker was recognized with respect to
MSCs source: CD271 was recommended to be used when characterizing
MSCs derived from bone marrow (Álvarez-Viejo et al., 2015).
Rather unsurprisingly, MSCs isolated from other species do not have
the same phenotype as those of human origin. It is generally accepted
that all MSCs lack CD45, a hematopoietic marker, as well as CD31, an
endothelial marker. Variations in surface antigen expression can in
addition result from factors released by helper cells at the initial stages
Fig. 1. Advantage of systemic administration
of oncolytic virus shielded by MSCs. Unshielded
oncolytic virus (e.g. myxoma virus), when ad-
ministered intravenously, elicits antiviral response
(NK cells, cytokines, mononuclear phagocyte
system (MPS), complement activation) leading to
virus clearance thus no oncolytic action. On the
contrary, shielding of viruses by suitable protec-
tive carrier e.g. mesenchymal stem cells (MSCs)
allows effective delivery to tumor bed and onco-
lytic action. Use of the therapeutic system
(“Trojan horse”) i.e. MSCs infected with oncolytic
virus enhances oncolysis and boosts acquired im-
mune response augmenting overall antitumor ef-
fect.
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of subculture. Also, in vitro expression of certain MSC markers is not
always concordant with their in vivo expression (Nery et al., 2013; Lv
et al., 2014).
2.2. Collection and safety
MSCs isolated from adult tissues can help resolving some ethical
issues raised with use of stem cells. From the economic perspective,
clinical applications of ADSCs seem advantageous to BM-MSCs due to
higher (several hundred-fold) intrinsic yield; adipose tissue is also more
abundant and more easily accessed, for example during liposuction. In
some cases, however, clinical benefits of BM-MSCs might prevail if
particular cell populations are used (Strioga et al., 2012).
Clinical use of MSCs requires rather large quantities of these cells,
which translates into extensive in vitro cell culture (Wang et al., 2012).
Cases of documented genomic instability of isolated stem cells were
reported, together with acquiescence of neoplastic features; since this
might affect tumor proliferation it would also be a problem for anti-
cancer therapies based on MSCs (Hanahan and Weinberg, 2011; Kim
and Park, 2017). BM-MSCs were also reported to acquire chromosomal
aberrations and undergo spontaneous transformation during long in
vitro culture, resulting in tumor formation in vivo (Wang et al., 2005).
Both preclinical and clinical data seem to indicate the safety of using
BM-MSCs and ADSCs. The vast majority of small-sized clinical trials
conducted with MSCs in regenerative medicine applications has not
reported any major health concerns, suggesting that MSCs-mediated
therapies are relatively safe (Herberts et al., 2011; Lukomska et al.,
2019). Biological activities such as proliferation and multipotency of
human adipose-derived adult stem cells (as opposed to embryonic ones)
were not clearly affected by wild-type reovirus challenge as evidenced
by survival, osteogenic and adipogenic differentiation potential assays
following treatment with this onolytic reoviruses (Park and Kim, 2017).
In the context of MSCs used solely as carriers of oncolytic constructs the
dimension of the safety issue could thus be somewhat less stringent. The
results support clinical use of human adipose-derived stem cells as an
effective cell carrier of oncolytic reovirus to maximize their tumor
tropism and anti-tumor activity. The concerns about the purported
ability to promote tumor growth and metastasis and overestimated
therapeutic potential of MSCs pertain rather to the field of regenerative
medicine (Volarevic et al., 2018). Nonetheless, in view of many con-
tradictory postulates, the debate continues concerning safety of using
MSCs in anticancer research and in clinical setting (Sensebé et al., 2012;
Kundrotas et al., 2016).
Four clinical trials using oncolytic virus-infected MSCs were un-
dertaken to date. All were/have been phase I studies. Three of them
have used BM MSCs and adenovirus and one study used ADSCs and
measles virus; their details can be found in Table 2.
2.3. Tissue tropism
Several studies have shown that injected MSCs are capable of mi-
grating directionally (homing) to specific tissues, including injury and
tumor sites. Migration of MSCs towards tumor bed is triggered by a
signaling cascade similar to that in wounds that do not heal (Dvorak,
1986). In addition to MSC-intrinsic factors (cell culture conditions, cell
population heterogeneity, expression of migratory molecules), the
tropism of MSCs towards cancerous tissues is affected by tumor site-
intrinsic properties such as oxygenation status, degree of vasculariza-
tion, inflammatory status, etc. (Najar et al., 2016).
Several types of molecules affecting MSCs migratory behavior have
been identified. They include growth factors and their receptors, e.g.
epidermal growth factor (EGF), vascular endothelial growth factor A
(VEGF-A), fibroblast growth factor (FGF), platelet derived growth
factor-AB (PDGF-AB), hepatocyte growth factor (HGF), transforming
growth factor β1 (TGF- β1) or insulin-like growth factor 1 (IGF- 1);
cytokines such as tumor necrosis factor α (TNF-α), Interleukin 6 (IL-6)
and Interleukin 8 (IL-8); chemokines e.g. CXCL-12 (C-X-C Motif
Chemokine Ligand 12), CCL-2 (C–C Motif Chemokine Ligand 2), CCL-3
(C–C Motif Chemokine Ligand 3) and their receptors, for example CCR4
(C–C Motif Chemokine Receptor 4) or CXCR4 (C-X-C Motif Chemokine
Receptor 4); also vascular cell and intercellular adhesion molecules
(VCAM and ICAM, respectively) have been implicated (Musiał-Wysocka
et al., 2019).
Tissue homing of MSCs following systemic injection results from
interactions between their surface proteins (such as integrins) with
blood vasculature components and target site-specific receptors or ad-
hesion molecules, including extracellular matrix (ECM) proteins such as
collagen, fibronectin or laminin.
Migratory patterns of MSCs largely depend on various cytokine /
receptor pairs such as SDF-1 (stromal cell-derived factor 1) / CXCR4,
SCF (stem cell factor) / c-Kit (tyrosine kinase receptor), HGF / c-Met
(hepatocyte growth factor receptor or HGFR), VEGF / VEGFR (vascular
endothelial growth factor receptors), PDGF / PDGFR (platelet derived
growth factor receptor), MCP-1 (Monocyte chemoattractant protein-1)
/ CCR2 (C–C Motif Chemokine Receptor 2) and HMGB1 (high-mobility
group protein 1) / RAGE (receptor for advanced glycosylation end)
(Momin et al., 2010; Shah, 2014).
Among these cytokine/receptor pairs the SDF-1 factor and its re-
ceptor CXC-4 (CXCR4) are important mediators of stem cell recruitment
to tumors (Suárez-Álvarez et al., 2012). It was demonstrated that ex-
pression of CXCR4 is turned off during cell culture (Phinney and
Prockop, 2007), but induction of cytokines (HGF, IL-6), under-
oxygenation conditions or its direct introduction via viral vectors re-
stores its expression (Bobis-Wozowicz et al., 2011).
Other important signaling pathways, affecting survival and stability
of MSCs, include PI3K (Chen et al., 2013), urokinase-type plasminogen
activator receptor (Gutova et al., 2008; Vallabhaneni et al., 2011) and
proteinase activated MMP1 receptor 1 (Ho et al., 2009).
Effective MSCs migration was demonstrated e.g. into glioma (Smith
et al., 2015), breast cancer (Ma et al., 2015) and liver cancer (Xie et al.,
2017). Tissue tropism confers MSCs with significant potential to ad-
vance anticancer treatment since it makes these delivery vehicles par-
ticularly attractive for targeting various therapeutic agents. For ex-
ample natural tropism to tumors shown by MSCs adds to better spread
of viruses if MSC-derived progeny particles can be produced in situ
(Koks et al., 2015).
2.4. Immunological properties
Immunological properties of MSCs affect significantly their ther-
apeutic potential. Low immunogenicity of allogeneic MSCs allows them
to avoid recognition and adverse immune response. Lack of co-stimu-
latory molecules expression and ensuing low immunogenicity of MSCs
results in no need for immunosuppression during allogenic transplan-
tation (Chulpanova et al., 2018a,b). However, MSCs perhaps should not
be considered truly immunologically privileged (at least not to the
extent claimed) but rather “immune evasive” as they could elicit a
humoral and cellular immune response in vivo (Ankrum et al., 2014).
These authors suggested also various strategies to protect MSCs from
immune detection and to prolong their persistence in vivo by en-
gineering MSC expression of immunosuppressive and immunoevasive
factors.
Little is still known about cellular components affecting im-
munogenicity of MSCs but the mechanisms of MSCs immunomodula-
tion (release of soluble factors, anergy, apoptosis induction) appear to
be coordinated with homeostatic functioning of the immune system via
a complex network of expression and cytokine responses (English,
2013). Immunomodulation of MSCs by activated cells of the immune
system is brought about by released proinflammatory cytokines and is
mediated by adhesion molecules (integrins) expressed on MSCs surface
(Wang et al., 2015). Depending on kind and concentration of these
cytokines, the immunomodulatory effects differ, revealing inherent
A. Hadryś, et al. European Journal of Pharmacology 874 (2020) 172991
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plasticity profiles of MSCs. Sizeable variability of such effects has also
been linked to donor source (Mattar and Bieback, 2015). micro-
environment. Evidence is now emerging that there exist a cross-talk
between MSCs and the status of local microenvironment. The latter
appears to be key in making MSCs immunosuppressive. It is clear that
MSCs can also modulate both innate and adaptive responses. Even
though MSCs themselves do not directly influence the immune system
they are capable of “re-educating” immune cells. Expression of nu-
merous integrin family receptors, as well as various adhesion mole-
cules, allows MSCs to interact with immune cells. This leads to gen-
eration of regulatory T lymphocytes (Treg) and B lymphocytes (Breg),
as well as antigen-presenting cells (APCs) and natural killer cells (NKs).
Such upregulation contributes to tolerogenic tumor environment and
ultimately results in immune tolerance; it is interleukin-10 (IL-10) re-
leased by these cells that plays the central role in multiple-pathway
immunomodulation exerted by MSCs (Franquesa et al., 2012; Ribeiro
et al., 2013; Najar et al., 2016).
To obtain a balanced therapeutic effect when using oncolytic viruses
in combination with MSCs, the expression (under conditions mimicking
physiological settings) of MSC-related immunogenic and im-
munosuppressive factors needs to be taken under consideration, along
with expression of therapeutic susceptibility biomarkers (Josiah et al.,
2010; Sensebé and Fleury-Cappellesso, 2013; Aurelian, 2016). The
immunosuppressive features of MSCs, together with active shielding of
the viral cargo from immune system surveillance add to the prevention
of inflammatory processes accompanying virotherapy and boost de-
structive power of oncolytic viruses.
2.5. Pro- and anti-cancer properties
The mechanisms underlying the relationship between MSCs and
immune cells in the tumor microenvironment are not fully understood
and remain a field of active research in order to gain a more coherent
picture of these interactions (Rivera-Cruz et al., 2017; Lin et al., 2019).
Studies have claimed MSCs to promote (e.g. in breast and colon can-
cers) or to inhibit (e.g. in liver, lung and pancreatic cancer) tumor
progression and metastasis using various mechanisms, mainly by re-
lease of soluble factors that activate or inhibit innate and adaptive
immune responses (e.g. Yulyana et al., 2015; Lin et al., 2016; Zhong
et al., 2017), stimulate or inhibit angiogenesis and maintenance of
cancer stem cell niche (Lin et al., 2019).
On the one hand, following accumulation of MSCs in sites of tumor
growth they differentiate into pericytes or tumor-associated fibroblasts
(TAF) and can co-form a growth-enhancing microenvironment (Musiał-
Wysocka et al., 2019). Some researchers claim that MSCs can support
malignant transformation, establishment and maintenance of cancer
cells, promotion of angiogenesis and neovascularization-sustaining
neoplastic tissues, metastasis formation and chemoresistance to drugs
(Nwabo Kamdje et al., 2017) and releasing cytokines such as vascular
endothelial growth factor (VEGF), interleukin-6 and 8 (IL-6 and IL-8),
transforming growth factor β (TGF-β), epithelial growth factor (EGF)
and platelet-derived growth factor (PDGF) (Chulpanova et al., 2018a).
On the contrary, MSCs infected with oncolytic viruses do not seem to
exert any of these protumorigenic effects (see Table 2). This does not
contradict tumor microenvironment triggering plasticity mechanisms in
MSCs, so that they contribute to the formation of cancer stem cell niche
and support stemness (Nwabo Kamdje et al., 2017).
On the other hand, the unique tropism of native and modified MSCs
towards inflammatory tissues continues to be exploited by novel anti-
cancer strategies. Some researchers who tested unmodified MSCs have
stressed their anti-cancer properties (Chanda et al., 2009; Abd-Allah
et al., 2014; Nasuno et al., 2014). MSCs are believed to inhibit tumor
growth by arresting cell cycle, suppressing proliferation, blocking PI3K/
AKT pathway and expressing suppressor genes (Chulpanova et al., 2018
a). Unmodified MSCs were shown to exert antineoplastic effect both in
vitro and in various animal tumor models; this was ascribed to MSCs-
released factors dampening proliferation of glioma, breast cancer and
liver cancer cells (Ho et al., 2013; Xie et al., 2013; Leng et al., 2014; Wu
et al., 2016a,b). Correct karyotype and no malignant transformation in
vivo were reported for BM-MSCs (Kim et al., 2009; Jones et al., 2013)
while chromosomal instability may just reflect cell ageing (Tarte et al.,
2010). The latter, resulting in irreversible halt of cell growth, is a
problem, however, when propagating MSCs (Ohtani and Hara, 2013). It
limits proliferative capabilities of primary cells (Shvarts et al., 2002),
attenuates therapeutic potential (Sepúlveda et al., 2014) and increases
the risk of malignant transformation (Shay and Roninson, 2004;
Gosselin et al., 2009).
Akimoto et al. (2013) reported that MSCs derived from different
tissues could either stimulate or dampen the proliferation of glioma
cells. In addition, MSCs from the same source and cultured in vitro,
promoted or inhibited tumor formation depending on the administra-
tion mode used (Jazedje et al., 2015). Intravenous injection of BM-
MSCs, conversely, repressed tumor growth in a murine Kaposi's sar-
coma model (Khakoo et al., 2006). Such contradictory results have been
noted both in vitro and in vivo for various types of tumors as well as for
tumor cell lines (Wu et al., 2016a,b; Larmonier et al., 2003). Similar to
BM-MSCs, MSCs from adipose tissue (ADSCs) also exhibit dual (pro- and
anti-cancer) properties; this was reported for breast cancer (Kucerova
et al., 2015) and prostate cancer (Cavarretta et al., 2010). Since con-
flicting reports have been published concerning therapeutic use of
ageing MSCs it should be borne in mind that this type of cell favors
migration and proliferation of cancer cells via galectin secretion
(ADSCs) (Li et al., 2015) or via secretion of IL-6 in the case of umbilical
cord-derived MSCs (UC-MSCs) (Di et al., 2014). However, when these
UC-MSCs with pro-tumoral properties were initially treated with IL-6,
they started to exert anti-tumoral effects (Wang et al., 2015). On the
contrary, it was demonstrated that ageing ADSCs inhibited tumor
growth but when they were stimulated by cancer cells their therapeutic
benefits vanished (Özcan et al., 2015). Also, ageing BM-MSCs were
reported to induce ageing of adjacent proliferating MSCs (Severino
et al., 2013).
3. Engineered MSCs
Despite low immunogenicity MSCs are believed not to persist for
long following systemic administration; therefore viral and non-viral
engineering strategies have been employed to protect MSCs from im-
mune detection and induce immunoevasive factors. They include forced
expression of decoy or inhibitory receptors through covalent conjuga-
tion chemistry or through insertion of antibody fusion proteins into the
cell membrane via palmitated protein G (PPG); increased persistence
can also be achieved through using immunoevasins or sustained release
of immunosuppressive factors (Ankrum et al., 2014).
MSCs have been successfully engineered to express various ther-
apeutic agents: small chemicals such as paclitaxel or cisplatin (Lin et al.,
2019), proapoptotic and suicide genes (Mueller et al., 2011; Altaner
et al., 2014), anti-angiogenesis factors (Chu et al., 2014) and im-
munomodulatory cytokines like interleukin-12, tumor necrosis factor
(TNF) α, interferons β and γ (Ryu et al., 2011; Shahrokhi et al., 2014;
Zhang et al., 2015).
Some neoplasms may be deficient or downregulated in specific
miRNAs therefore exosomes, which contain a variety of miRNAs, or
which can be enriched in them, can transfer such cargo to cancer cells.
MSCs, or rather exosomes derived from MSCs, can be thus used as
carriers for such therapeutic miRNAs. However, in view of somewhat
discordant results of this approach it has been postulated that MSCs
should first be engineered in order to obtain stable expression of some
cancer killer genes before exosomes’ isolation (Lin et al., 2019). MSCs
engineering has created new prospects for combinations of MSC-based
cell therapies with other therapeutic modalities, e.g. immune check-
point blockade (Conry et al., 2018), nanotherapeutics (Lawler et al.,
2017; Garofalo et al., 2018; Kalimuthu et al., 2018). These, and other
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therapeutic approaches have been extensively described elsewhere (e.g.
Bitsika et al., 2013; Chulpanova et al., 2018 a). Some of these studies
have advanced from preclinical to phase I/II clinical trials; however,
cell-based therapies have a number of potential disadvantages mediated
by the properties of cells (Chulpanova et al., 2018 b).
4. Engineered oncolytic viruses
The renewed interest in clinical development of oncolytic viruses is
in part the result of genetically modified viral constructs that can confer
increased tissue specificity and initiate apoptosis of cancer cells, induce
specific anti-cancer responses or render cancer cells more sensitive to
specific chemotherapies or to radiotherapy.
Examples of such weaponized and improved vectors include: re-
combinant HSV-1 virus for treatment of metastatic breast carcinoma or
melanoma; recombinant measles virus (MV) for treatment of myeloma
and prostate cancer; recombinant Newcastle disease virus (NDV) sti-
mulating immune system and cytokine release in liver cancer; vesicular
stomatitis virus (VSV) exploiting defective interferon pathway in cancer
cells; HSV-1 virus with deleted thymidine kinase gene or Ad5/3-Δ24
adenovirus modified to bind to integrins αvβ3 and αvβ5 (highly ex-
pressed on ovarian cancer cells), and which is currently being in-
vestigated in clinical trials (Kaufman et al., 2015). The immense po-
tential of oncolytic virotherapy has been convincingly demonstrated by
recombinant herpes simplex virus type 1 (HSV-1), called Talimogene
laherparepvec (T-VEC) approved in 2015 for treatment of metastatic
melanoma (FDA in the US, Reuters. 27 October 2015; EMA in the EU,
Onclive, 2015). T-VEC efficacy is rooted in the deletion of two non-
essential viral genes resulting in selective viral replication ability and
promotion of regional and systemic antitumor immunity; expression of
human granulocyte macrophage colony-stimulating factor (GM-CSF)
allows local GM-CSF production triggering recruitment and activation
of antigen-presenting cells with subsequent induction of tumor-specific
T-cell responses. The drawback of T-VEC is that its efficacy against
disseminated disease appears contingent upon intralesional adminis-
trations (Senzer et al., 2009; Andtbacka et al., 2015). This, rather em-
phatically, accentuates the rationale behind efforts to further improve
systemic oncovirotherapy.
T-cell effector functions can be enhanced by delivering into tumor
microenvironment certain transgenes via genetically engineered onco-
lytic viruses. Specific antigen expression on tumor cells can be com-
bined with action of CAR-T cells expressing a receptor recognizing
specifically cancer-associated antigen. Promising results were reported
in preclinical studies combining CAR-T cells with oncolytic viruses
armed with cytokines, chemokines, BiTEs (Bi-specific T-cell engagers),
or immune checkpoint inhibitors (Guedan and Alemany, 2018;
Harrington et al., 2019).
5. Immune checkpoint inhibitors and oncolytic therapy
The recent approval by the US Food and Drug Administration (FDA)
of two different CAR-T cell therapies (for the treatment of leukemia and
lymphoma) represents a landmark in the development of cancer im-
munotherapies. CAR-T cells are revolutionizing the field of cancer
therapy, together with immune checkpoint blockade therapy (Guedan
and Alemany, 2018).
Immune checkpoint inhibitors unblock T cell inhibitory signals and
trigger antitumor T-cell responses. Checkpoint proteins targetable by
therapeutic antibodies include proteins found on T cells or cancer cells,
e.g. PD-1/PD-L1 and CTLA-4/B7-1/B7-2 (e.g. Russell and Peng, 2018).
Oncolytic viruses lyse tumor cells as part of viral replication cycle;
by inducing changes in the tumor microenvironment (“cold” into “hot”
tumor transformation) they can also increase locally the number of
immune effector cells. This outcome can sensitize tumors to checkpoint
inhibitors involving e.g. PD-1/PD-L1 and CTLA-4/B7-1/B7-2 molecules
and/or antibodies. The effectiveness of such improved approach was
demonstrated in metastatic melanoma for intralesional injections of
oncolytic virus (T-VEC) and anti-PD-1 treatment (Haanen, 2017).
Administration of checkpoint inhibitors (either systemically or via
viral transgene expression) along with oncolytic vectors has proven
successful in multiple clinical and preclinical models (LaRocca and
Warner, 2018; Sivanandam et al., 2019). Synergy gain could also be
expected with oncolytic virus-loaded MSCs combined with immune
checkpoint inhibitors. Interestingly, a novel recombinant myxoma virus
construct (vPD1) designed to secrete a soluble form of PD-1 from host
cells was recently reported to be able to accumulate in tumor tissue;
MYXV synergy with PD-1 blockade resulted in complete response in ca.
60% of mice (Bartee et al., 2017). All these novel combination regimens
will likely have a dramatic impact in the years to come.
Two clinical trials exploring oncolytic virus combination with
checkpoint inhibitor stand prominently and both involve T-VEC. The
trial involving combination with Ipilimumab (an anti-CTLA-4 antibody)
yielded significantly higher response rates of the combination therapy
arm than those of the monotherapy arm and without dose-limiting
toxicities. Importantly, half of the patients demonstrated abscopal re-
sponses in distant, non-injected visceral lesions (Chesney et al., 2018).
The clinical trial involving T-VEC combination with, pembrolizumab
(an anti-PD-1 antibody) also yielded impressive objective response rate
of 62% while in 33% of patients the response was complete. The
combination therapy yielded elevated PD-L1 protein expression and
increased CD8+ T cells on several tumor cell subsets suggesting that
oncolytic virotherapy did improve the efficacy of anti-PD-1 therapy by
altering the tumor microenvironment (Ribas et al., 2017).
6. Non-systemic anticancer therapy with oncolytic virus-loaded
MSCs
Use of MSCs as a non-systemic carrier of oncolytic viruses has been
attempted with varying success in the therapy of glioma, colon, pros-
tate, ovary, breast, liver and lung cancer, lymphoblastic leukemia and
also in treating melanoma metastases to the brain (e.g. Stuckey and
Shah, 2014; Ramírez et al., 2015; Nowakowski et al., 2016; Brittany
et al., 2017; Russell et al., 2019).
The results of preclinical studies involving non-systemic adminis-
tration of MSCs infected with various “armed” oncolytic viral constructs
are included in Table 1.
Oncolytic herpes simplex virus (oHSV) has been among the most
frequently tested in conjunction with MSCs encapsulated in bio-
compatible synthetic extracellular matrix (sECM). Duebgen showed
that MSCs-sECM were able to support amplification of the tested oHSV-
TRAIL construct (TNF-related apoptosis-inducing ligand) and triggering
apoptosis in glioma cell lines nonpermissive to oHSV and resistant to
TRAIL. MSC-mediated delivery could overcome the problem associated
with direct oncolytic virus injection into resection cavities and negli-
gent curative effect (Duebgen et al., 2014).
A few studies demonstrated circumvention of pre-existing anti-viral
immunity and enhanced therapeutic outcomes when using oncolytic
virus-infected MSCs. Mader and colleagues tested MV-infected MSCs
(adipose tissue-derived) in mice bearing different orthotopic human
ovarian tumor xenografts. Intraperitoneally administered virus-loaded
MSCs were shown to traffic to and co-localize with the xenografts
transferring measles virus infection and significantly extending survival
of mice passively immunized with antimeasles antibodies (Mader et al.,
2009).
Various adenoviral constructs have been extensively tested in non-
systemic therapies in conjunction with MSCs. Using the syngeneic
murine CMT64 lung cancer cell line to create a human adenovirus semi-
permissive tumor model, Rincón et al. demonstrated the homing ca-
pacity of adenovirus-loaded murine mesenchymal stem cells (mCelyvir)
to the induced tumors. A combined treatment with mCelyvir and in-
tratumoral injections of ICOVIR5 (the adenoviral construct itself)
showed synergy compared to ICOVIR5 alone. The therapeutic effects of
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combined therapy were accompanied by increased tumor infiltration by
recruited CD8+ and CD4+ T lymphocytes (Rincón et al., 2017).
Antitumor efficacy studies of syngeneic or allogeneic murine me-
senchymal stem cells infected with oncolytic adenovirus ICOVIR5 (i.e.
Celyvir system) have suggested that the use of both types of Celyvirs
leads to higher infiltration of CD45+ cells and leukocytes in the core of
murine lung adenocarcinoma tumors (Morales-Molina et al., 2018).
Peritoneal cavity delivery of a conditionally replicative survivin
promoter-driven adenovirus by allogeneic neural stem cells was shown
to improve treatment of cisplatin-resistant ovarian metastatic tumors.
The survivin promoter was used to drive the oncolytic construct since
this protein is highly expressed in ovarian cancer cells (Mooney et al.,
2018).
An oncolytic adenoviral construct “armed” with epidermal growth
factor receptor (EGFR)-targeting bispecific T-cell engager (cBiTE)
combined by Barlabé and colleagues with menstrual blood-derived
mesenchymal stem cells (MenSCs) resulted in stronger anti-tumor po-
tency of such armed ICOVIR15 construct both in vitro and in vivo, as
compared to the unarmed ICOVIR15 virus (Barlabé et al., 2019).
Suppression of prostate cancer tumor growth in subcutaneous
murine xenograft model was reported for intratumoral administration
of human mesenchymal stem cells modified with E1 A/B adenoviral
genes (necessary for viral replication) and used as carrier for replica-
tion-defective adenovirus expressing p14 and p53 or conditionally re-
plicating oncolytic adenovirus (Muhammad et al., 2019).
CXCR4 promoter-driven conditionally replicating oncolytic adeno-
virus (CRAd) loaded into human mesenchymal stem cells (hMSCs) was
used for intracranial treatment targeting glioblastoma, the most deadly
brain tumor. Virus-loaded hMSCs were demonstrated to migrate in vitro
and release CRAds that infected U87MG glioma cells. When injected at
a distance of 5 mm anterior to the tumor site, virus-loaded hMSCs were
able to migrate to the tumor site and deliver 46-fold more viral copies,
as compared to the injection of adenovirus alone (Sonabend et al.,
2008).
Martinez-Quintanilla et al. reported that intratumoral injections of
conditionally replicating adenovirus expressing soluble hyaluronidase
(ICOVIR17) mediated degradation of hyaluronic acid (HA), a compo-
nent of extracellular matrix (ECM) and enhanced viral spread bringing
about major antitumor effect; however, ICOVIR17 loaded into human
ADSC encapsulated in biocompatible synthetic extracellular matrix
(sECM-MSC) demonstrated even greater efficacy in a clinically relevant
mouse model of GBM resection (Martinez-Quintanilla et al., 2015).
Studies of ADSCs infected with myxoma virus (MYXV), a promising
nonhuman poxvirus candidate for oncovirotherapy demonstrated that
upon intracranial administration the infected cells were able to migrate
to and cross-infect experimental glioblastoma multiforme (GBM) foci,
even away from the primary tumor site (Josiah et al., 2010). Sub-
sequent study of Pisklakova and colleagues convincingly showed that
MYXV knock-out construct devoid of a viral gene called M11L reg-
ulating apoptosis can trigger increased cell death in infected brain
tumor-initiating cells (BTIC) which are largely responsible for dead-
liness of glioblastoma. Their elimination resulted in enhanced survival
of immunocompetent mice burdened with BTIC-seeded glioma
(Pisklakova et al., 2016). This seminal result was achieved with or-
thotopic delivery of the virus which only emphasizes the dormant po-
tential of cell-mediated delivery of such myxoma construct.
Adipose tissue-derived stem cells (ADSCs) used as vaccinia virus-
amplifying Trojan horse were claimed by Draganov et al., claim how-
ever that allogeneic differences associated with the induction of anti-
stem cell cytotoxicity and thus allogeneic responses from both innate
(NK)- and adaptive (T)- immune cells might compromise therapeutic
efficacy through direct elimination of the stem cells or the induction of
an anti-viral state, which can block the potential of the Trojan horse to
amplify and deliver vaccinia virus to the tumor; assays detecting im-
portant patient-specific differences in the immune responses to the
virus and stem cells were postulated (Draganov et al., 2019).
7. Systemic anticancer therapy with oncolytic virus-loaded MSCs
The results of preclinical studies involving systemic administration
of MSCs infected with various “armed” oncolytic viral constructs are
summarized in Table 1.
In order to eliminate disseminated melanoma metastases in the
brain, Du and al. developed suitable models in immunocompromised
and immunocompetent mice and tested the efficacy of oncolytic herpes
simplex virus delivered by MSCs. Intracarotid administration of MSC-
oHSV, but not of oHSV alone, effectively tracked to metastatic lesions
and significantly prolonged the survival of brain tumor-bearing mice. A
combination of MSC-oHSV and PD-L1 blockade in a syngeneic model
increased IFNγ-producing CD8+ tumor-infiltrating T lymphocytes re-
sulted in significantly increased survival (Du et al., 2017).
A combination involving MSCs from different sources and infected
with a HER2-retargeted oncolytic HSV and evaluated in two murine
models of metastatic cancers following a single iv. injection of infected
MSCs showed the highest concentration of carrier cells and viral gen-
omes in the lungs. Viral genomes persisted throughout the body for at
least two days. The treatment significantly inhibited growth of ovarian
cancer lung metastases in nude mice and reduced by more than one-half
the burden in case of breast cancer metastases to the brain in NSG mice
(Leoni et al., 2015).
A study of orthotopic hepatocellular carcinoma model in SCID mice
immunized with human neutralizing antibodies and treated with atte-
nuated MV and BM-hMSCs has shown that cell-associated MVs were
protected from antiviral antibodies. The authors claimed this strategy
may elude immunity against MV in most of the cancer patients (Ong
et al., 2013).
Human BM-MSCs were also demonstrated to efficiently deliver
measles oncovirotherapy to precursor B-lineage acute lymphoblastic
leukemia (ALL) cells in a xenograft model. BM-MSCs were successfully
loaded with MV ex vivo, and MV was amplified intracellularly without
signs of toxicity. Following systemic treatment 16 adults with acute
lymphoblastic leukemia and receiving immunosuppressive drugs de-
veloped high-titer anti-MV antibodies (Castleton et al., 2014).
More than a decade ago MSCs loaded with oncolytic adenoviruses
were demonstrated to improve the bioavailability of systemically in-
jected oncolytic adenoviruses in orthotopic murine models of lung and
breast cancer (Hakkarainen et al., 2007).
hMSCs were shown to be effective cell carriers for systemic delivery
of a relaxin (RLX)-expressing oncolytic Ad (oAd/RLX) which is able to
degrade dense tumor extracellular matrix of highly desmoplastic pan-
creatic cancer overcoming poor delivery of oAd. Complex with biode-
gradable polyethyleneimine-conjugated polymer enhanced the inter-
nalization of oAd into hMSC, leading to superior viral production and
release from hMSCs, along with high RLX expression. Systemic ad-
ministration of oAd/RLX-PCDP-treated hMSCs yielded strong antitumor
effect in pancreatic tumor model due to superior viral replication (Na
et al., 2019).
Application of human umbilical cord-derived MSCs (HUMSCs) was
reported in eliminating postsurgical residuals and metastasis of hepa-
tocellular carcinoma. Stem cells were loaded with a conditionally re-
plicative adenovirus (CRAd) containing E1A gene dually regulated by
α-fetoprotein promoter and microRNA-122 target sequence. Besides
showing production of CRAd by differentiated HUMSCs in vitro Yuan
et al. demonstrated hepatocyte-like transformation of HUMSC in the
microenvironment of orthotopic or heterotopic hepatoma and inhibi-
tion of growth of both orthotopic and subcutaneous hepatic xenograft
tumors in mice (Yuan et al., 2016).
Effectiveness of systemically delivering a hepatocellular carcinoma-
targeted oncolytic adenovirus encoding Wnt-inhibiting decoy receptor
sequence (WNTi) and loaded into MSCs (HCC-oAd-WNTi/MSC) was
compared to control hepatocellular carcinoma (HCC)-targeted onco-
lytic adenovirus (HCC-oAd) shielded by mesenchymal stem cells.
Intravenously injected HCC-oAd-WNTi/MSC therapeutic system homed
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to HCC tumors and led to high virion accumulation in the tumors, ul-
timately resulting in effective growth inhibition. In vitro oncolysis of
HCC cells was demonstrated under both normoxic and hypoxic condi-
tions confirming HCC-oAd-WNTi hypoxia responsiveness (Yoon et al.,
2019).
Engineered chimeric oncolytic adenoviruses were also used in stu-
dies targeting colorectal tumor cells with menstrual blood-derived
MSCs. Such adenoviruses indeed accumulated in colorectal tumors and
mediated marked inhibitory effects (Guo et al., 2019).
Owing to suppressed production of interferon-γ (IFN-γ) by activated
T cells, an improved delivery, enhanced dissemination and increased
persistence of adenovirus delivered by MSCs was observed in a breast
fibrosarcoma model when compared to virus administration alone
(Ahmed et al., 2010).
In testing therapeutic strategies for metastatic breast cancer, the
effectiveness of homing to the tumor site and extended animal survival
were compared between intravenous injections of conditionally re-
plicating Ad (CRADs) loaded into hMSCs and CRAd alone using the
MDA-MB-231 murine pulmonary breast metastasis model (Stoff-Khalili
et al., 2007).
A significant therapeutic effect obtained in systemic treatment of
gallbladder carcinoma (GBC) was observed using human BM-MSCs in-
fected with myxoma virus (MYXV), almost matching intratumoral in-
jections of MYXV. This demonstrated MYXV to be effectively delivered
by MSCs to sites distant from the injection site, making intravenous
injection of MYXV a possible therapeutic approach in treating GBC
tumors (Weng et al., 2014).
Improved survival and eradication of glioma was reported for Delta-
24-RGD adenoviral construct loaded into GFP-labeled hMSCs and de-
livered into intracarotid artery of mice harboring orthotopic U87MG or
U251–V121 xenografts via infection of human glioma and release of
Delta-24-RGD improving survival and tumor eradication (Yong et al.,
2009). This demonstrated that glioma can be successfully targeted
systemically. Myxoma virus was also capable of restoring apoptosis in
brain tumor initiating cells (BTIC) by transfer of a knockout construct
devoid of M011L viral gene that regulates apoptosis (Pisklakova et al.,
2016). Although this result was not achieved via systemic administra-
tion with MSCs, attempts at systemic delivery using this construct are
now underway in our laboratory.
8. Limitations of MSC use in systemic therapy
One of the barriers encountered by oncolytic viruses upon in-
travenous administration (as for any other viruses), is the host response:
circulating antibodies, cytokines, complement proteins and immune
cells in the bloodstream eliminate the viral particles; those that manage
to reach particular organs are then scavenged by immune system cells.
This largely explains the generally ineffective outcome of intravenous
delivery of unshielded virus and tumor tissue targeting (Fig. 1.). This is
especially crucial when contemplating virotherapy of disseminated or
hard-to-reach tumor sites. In the case of intratumoral administration,
even though anti-viral response from the immune system is diminished,
the immunosuppressive tumor microenvironment still can drastically
limit replication of the therapeutic oncolytic construct. Thus, the ideal
systemic cell carrier should be easily infected ex vivo by the therapeutic
oncolytic virus, without being overly permissive, i.e. without cyto-
toxicity profile preventing transit of the therapeutic agent to target)
yet allowing replication of progeny virus to infect targeted cancer cells
(Harrington et al., 2019).
MSCs have been extensively reported as carriers for oncolytic
viruses providing them with effective shield against neutralizing host
effects and targeting them to tumor sites (e.g. Bosu and Kiperos, 2008;
Willmon et al., 2009; Shi et al., 2010; Josiah et al., 2010; Sensebé and
Fleury-Cappellesso, 2013; Zhao et al., 2015; Leoni et al., 2015;
Aurelian, 2016).
Some researchers have raised, nonetheless, the issue of limited
persistence of MSCs upon systemic injection and, actually, low effi-
ciency in targeting damaged/inflamed tissues (Lee et al., 2009; von
Bahr et al., 2012; Ranganath et al., 2012).). Poor expression of adhesion
or homing ligands responsible for inflammation site homing can be
negatively affected during in vitro expansion of MSCs (Wu and Zhao,
2012; Hocking, 2015). Enhanced homing of MSCs to inflammation
sites, can be engineered by conjugating specific antibodies or by other
approaches such as triggering transient overexpression of CD44, the
hyaluronic acid (HA) receptor (Corradetti et al., 2017). Other ther-
apeutic approaches to enhance systemic delivery of MSCs include: en-
gineered hyaluronidase-mediated degradation of extracellular matrix
(ECM), ultrasound cavitation or temporal vasodilation enhanced viral
delivery (Martinez-Quintanilla et al., 2015; Harrington et al., 2019).
Conversely, blocking CD44 with antibodies or engineering CD44 on the
MSC membrane should reduce homing of intravenously administered
MSC to inflammatory sites.
Intravenous administration of cell-shielded oncolytic viruses is not a
very invasive procedure, whereas local injections in some instances can
be difficult to achieve. Lung capillaries can form, however, a first-pass
barrier for MSCs because of their size. Although this might be beneficial
for treating certain medical conditions (e.g. oncolytic therapy of lung
neoplasia) it could also be a barrier for systemic therapy of peripheral
tumors (Fischer et al., 2009). Intravenous administration of MSCs leads
to strong initial accumulation in the lungs (Gholamrezanezhad et al.,
2011). Adhesion molecules on capillary endothelium probably con-
tribute to retention of MSCs in the lung; blocking CD49d decreases the
number of lung-trapped MSCs (Nystedt et al., 2013). Interestingly,
adhesion of MSCs to lung endothelium can be attenuated by treatment
with pronase following which they are found elsewhere in greater
numbers (Kerkelä et al., 2013).
The first-pass problem with intravenous administration could per-
haps be solved or reduced by intraarterial infusion of MSCs. This pro-
cedure avoids the first-pass lung retention effect and results in de-
creased accumulation of MSCs in lungs (Walczak et al., 2008; Mäkelä
et al., 2015), thus legitimizing this procedure when trying to achieve
improved targeting of tissues in peripheral locations. Available data
suggest that intraarterial administration of MSCs contributes to tissue
biodistribution and bioavailability of MSCs in clinically relevant set-
tings. This might have important implications for treating pathologies
such as gliomas, for example. It has been shown that delivery of MSCs
through the internal carotid artery facilitates their migration and
homing into injured brain areas compared with administration via the
femoral vein (Nakamizo et al., 2005; Walczak et al., 2008; Doucette
et al., 2011).
Improvements in engineering of viral constructs and MSCs, coupled
with the “Trojan horse” concept has led to a wealth of novel therapeutic
possibilities. With precautions and barriers to overcome, MSC-mediated
delivery could become a promising therapeutic delivery platform.
9. MSC-mediated oncolytic virotherapy - clinical studies
There have been a few clinical studies combining the use of various
MSCs and oncolytic viruses (see Table 2).
The first clinical study (EudraCT Number: 2008-000364-16) was
based on an exploratory study (García-Castro et al., 2010) using CE-
LYVIR (autologous MSCs infected with ICOVIR-5, a modified adeno-
virus with replication restricted to cells with an activated RB pathway)
to treat metastatic neuroblastoma and other pediatric refractory ma-
lignancies (Ewing's sarcoma with bone or bone marrow metastases,
metastatic osteogenic sarcoma, metastatic soft tissue sarcoma, meta-
static rhabdomyosarcoma) as well as on a more detailed study (see:
Melen et al., 2016). The clinical study was prematurely ended and no
results seem available.
Another study with CELYVIR, NCT 01844661 (Phase I) also made
use of bone marrow-derived autologous mesenchymal stem cells in-
fected with ICOVIR-5 for systemic treatment of metastatic solid tumors
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in children and adults; the study was completed in 2016. The combi-
nation of MSCs and oncolytic adenovirus was found to be safe war-
ranting further evaluation in the phase II setting. No further informa-
tion is available.
The NCT 02068794 trial is a phase I/II study of side effects and best
dose of intraperitoneal administration of adipose tissue-derived me-
senchymal stem cells (ADSC) infected with oncolytic measles virus
encoding thyroidal sodium iodide symporter (MV-NIS); the trial is set
for recurrent ovarian cancer patients. The study is ongoing.
Yet another study exploring ICOVIR-5 is EudraCT Number 2019-
001154-26 in which allogeneic BM-MSCs have been used
(AloCELYVIR); it is a feasibility trial of the combination of AloCELYVIR
with chemotherapy and radiotherapy used to treat children and ado-
lescents with relapsed or refractory extracranial solid tumors. The study
is ongoing.
Another study involving administration of allogeneic bone marrow-
derived human mesenchymal stem cells loaded with oncolytic virus is
NCT03896568; in this instance carrier BM-hMSCs are infected with
DNX-2401, an oncolytic adenovirus with integrin binding RGD-4C
motif (Delta-24-RGD); the therapeutic construct is administered by
transfemoral super-selective endovascular intracranial injection (i.e.
intraarterial) to patients with recurrent glioblastoma (GBM), glio-
sarcoma or wild-type IDH-1 anaplastic astrocytoma.
Also neural stem cells loaded with construct have been explored in a
clinical setting (NCT03072134) to deliver CRAd-survivin-pk7 a con-
ditionally replicative oncolytic adenovirus with survivin promoter and
fiber-modified with polylysine (Kiyokawa and Wakimoto, 2019).
10. Future directions
Even though the preclinical studies are highly promising, effec-
tiveness of oncolytic virotherapy remains suboptimal, with only a
fraction of patients undergoing complete tumor regression (called “elite
responders”) but the majority still do not (Bell and McFadden, 2014).
Effectiveness of virotherapy ultimately relies on eliminating factors that
impede efficient virus delivery to the target sites, particularly for dis-
seminated cancer burden (e.g., insufficient numbers of tumor-pene-
trating viral particles) (Marchini et al., 2016).
Future advances in oncolytic virotherapy will likely come from
engineered viral constructs and their increasingly sophisticated car-
riers: transgene-armed oncoviral platforms interfering with host cel-
lular defenses (e.g. by manipulating cellular DEAD box RNA helicases
(e.g. Rahman et al., 2017) or allowing regulation of intracellular sig-
naling pathways restoring apoptosis (e.g. in brain tumor initiating cells,
see Pisklakova et al., 2016), or focusing on some highly overexpressed
targets (such as interleukin 13 and ephrin receptors in glioblastoma)
with ligand-cytotoxic agent combination warheads or encapsulating
carrier cells infected with oncolytic viruses in synthetic extracellular
matrices that would allow prolonged release of therapeutic agents
(Kauer et al., 2012).
As of the end of 2019, therapy of the deadliest cancers continues to
be a challenge although breakthroughs seem to be within reach. Still,
for systemic oncolytic virotherapy there remains a stern firewall: ef-
fective delivery. Smart cellular carriers, including engineered MSCs,
stand a good chance to become the platform allowing authorized access
of viral oncolytics to metastatic lesions through this firewall.
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